Placebo Control

Maybe those pesky sites are good for something after all.  It's been six years since Pfizer boldly announced the launch of its "...

Are competing trials slowing yours down? Probably not. If they don't like your trial, EVERYTHING ELSE IN THE WORLD is competition fo...

Last week, the Tufts Center for the Study of Drug Development unleashed the latest in their occasional series of dire pronouncements about...

Here's a fitting postscript to yesterday's article about wishful-thinking-based enrollment strategies : we received a note from a re...

'Competitive enrollment' is exactly that. This is a graph I tend to show frequently to my clients – it shows the relative enrollm...

ENACCT has released its final report on the outcomes from the National Cancer Clinical Trials Pilot Breakthrough Collaborative (NCCTBC) , a...

Pretty much everyone involved in patient recruitment for clinical trials seems to agree that "metrics" are, in some general sense,...

[Note: this post is an excerpt from a longer presentation I made at the DIA Clinical Data Quality Summit, April 24, 2012, entitled Delight t...

In what appears to be, oddly enough, an exclusive announcement to Pharmalot, Pfizer will be discontinuing its much-discussed “Trial in a b...

A few years back, I was working with a small biotech companies as they were ramping up to begin their first-ever pivotal trial. One of the ...

Modern clinical trials in the pharmaceutical industry are monuments of rigorous analysis. Trial designs are critically examined and debated ...